The present disclosure provides a microbiological treatment system including a hydration system and microbiological degradation systems. The hydration system may include a gas-liquid mixing chamber, a gas inlet, a gas outlet, a liquid inlet, and a liquid outlet, the latter four being fluidly coupled to the chamber. The gas inlet is configured to introduce an ethylene oxide exhaust gas into the chamber to mix with an aqueous solution to form an ethylene oxide exhaust liquor. The liquid outlet is configured to discharge the ethylene oxide exhaust liquor. Each microbiological degradation system may include a degradation chamber containing degradation bacteria including one of anaerobic bacteria, facultative bacteria, or aerobic bacteria. The degradation chambers of the microbiological degradation systems may be in fluid communication sequentially in a predetermined degradation sequence, with the most upstream in the degradation sequence having a liquid inlet in fluid communication with the liquid outlet.

A media supplement for culturing anaerobic bacteria is provided which comprises a filtrate of eilluent from a chemostat vessel in which a target bacterial ecosystem has been culnn-ed. Methods of using the supplement for culturing or isolating anaerobic microbial strains or cormmmities, particularly anaerobic bacteria from the human gut, are also provided.

A process for culturing Clostridium saccharoperbutylacetonicum cells, which are capable of growing on gamma-cyclodextrin in a liquid culture medium in a culture vessel. Also disclosed is a process for producing a bio-product, the process comprising culturing Clostridium saccharoperbutylacetonicum cells, which are capable of growing on gamma-cyclodextrin in a liquid culture medium in a culture vessel.

In certain aspects, described herein are methods, bacteria, and compositions for the reduction of the amount, activity and/or proliferation of colonic group 3 innate lymphoid cells (ILC3s) and for the treatment and/or prevention of diseases associated with pathological immune responses, such as inflammatory bowel diseases.

The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a16S rRNA sequence SEQ ID NO: 2.

Provided are aqueous fermentation feedstocks comprising glucose monomers at a concentration of less than 50 gram/Liter (g/L) of the total feedstock, water-soluble dextrose oligomers at a concentration in a range between 50 g/L and 300 g/L of the total feedstock; and water. Further provided are methods of production thereof and uses thereof in the production of single cell protein and/or ethanol.

Species of human-derived bacteria belonging to the Clostridia class have been shown to induce accumulation of regulatory T cells (Treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

The present disclosure relates to a Clostridium sp. JS66 strain producing metabolites having 4 to 6 carbon atoms in a high yield. The strain produces metabolites having 6 carbon atoms in a significantly high yield while reducing the production of acetic acid and ethanol as by-products.

Provided is a tetanus toxin protein variant, the tetanus toxin protein variant comprising a C fragment of the tetanus toxin protein and a partial fragment of a translocation region of the tetanus toxin protein. Further provided is a proteoglycan conjugate, the proteoglycan conjugate comprising a polysaccharide from Streptococcus pneumoniae and a truncated tetanus toxin protein. Also provided is a method for improving immunogenicity, the method comprising the following steps: providing a proteoglycan conjugate comprising a polysaccharide from Streptococcus pneumoniae and a truncated tetanus toxin protein.